Oligopeptide-68 and Nonapeptide-1

Oligopeptide-68: β-White (trade name of the liposomal preparation), TGF-β-derived brightening peptide. Nonapeptide-1: Melanostatine-5 (trade name), Met-Pro-D-Phe-Arg-D-Trp-Phe-Lys-Pro-Val-NH₂, MC1R antagonist peptide

Skin & cosmetic

Awaiting medical reviewEN ES DE FR PT ZH+ Follow for updates

Summary

Class: Oligopeptide-68: synthetic peptide modelled on a region of TGF-β1, supplied in liposomes. Nonapeptide-1: synthetic nine-amino-acid α-MSH analogue engineered to block rather than activate the MC1R
Mechanism: Both reduce melanin production upstream of tyrosinase: oligopeptide-68 by lowering MITF (the master pigment-gene switch); nonapeptide-1 by stopping α-MSH from binding its receptor
Routes studied: Topical only
Dose range reported: Oligopeptide-68: manufacturer study used a serum with the liposomal preparation at manufacturer-recommended 1–5% of formula †. Nonapeptide-1: manufacturer recommendation 1–5% of the commercial solution, i.e. peptide in the parts-per-million range †
Half-life: Not applicable topically; no systemic data
Storage: Finished products: room temperature, protect from light. Raw materials: refrigerate
Regulatory status: Both permitted cosmetic ingredients; no medicinal approval. Brightening claims are restricted in some markets (e.g. Korea's functional-cosmetic system)

Doses are as reported in studies or by the community — never recommendations.

1What it is

These are two peptide approaches to the same cosmetic goal — fewer dark spots and a more even tone — that work at different points in the pigment pathway, and they are often formulated together or with classical brighteners (niacinamide, tranexamic acid, arbutin).

Oligopeptide-68 was designed by a French cosmetic-ingredient company to mimic the effect of TGF-β1 on melanocytes. TGF-β1, among its many actions, turns down MITF, the transcription factor that controls tyrosinase and the other melanin enzymes. The peptide is delivered in liposomes under the name β-White.

Nonapeptide-1 was developed by a Spanish cosmetic-peptide company and is sold as Melanostatine-5. It is a modified α-MSH fragment — structurally a relative of acetyl hexapeptide-1 (#187) — but engineered so that it binds MC1R without activating it. It therefore blocks the hormone's "make pigment" signal, especially the UV-induced part.

Both are synthetic molecules inspired by human signalling proteins.

2How it's thought to work

Oligopeptide-68. activates the RAS/ERK pathway as TGF-β1 does, leading to phosphorylation and degradation of MITF. Less MITF means less tyrosinase, TRP-1 and TRP-2, so less melanin, for both pigmentation and the extra pigment triggered by UV and α-MSH.

Nonapeptide-1. competitive antagonist at MC1R. With the receptor blocked, α-MSH cannot raise cAMP, so MITF and tyrosinase are not induced. It should mainly blunt new pigment formation rather than remove existing melanin.

Shared limit. neither removes pigment already in the epidermis; visible lightening depends on normal skin turnover (weeks) and on preventing new UV-driven pigment, which is why every study and manufacturer insists on daily sunscreen.

Proposed: a cosmetic peptide aimed at the same tyrosinase step, marketed for even skin tone. The mechanism drawn is shared with the other brighteners in this class; what differs between them is the sequence, not the target.Schematic — not to scale

3What the research shows

Oligopeptide-68, in vitro

In B16-F10 melanoma cells the peptide reduced MITF and tyrosinase protein, blocked α-MSH-induced increases in MITF, TRP-1 and TRP-2, and reduced melanin dose-dependently (manufacturer paper in Cosmetics & Toiletries). Melanoma cell lines are a standard but imperfect model of normal melanocytes.

Oligopeptide-68, topical clinical

Manufacturer study: 23 Asian women aged 33–55 with at least one dark spot applied a serum containing the liposomal peptide twice daily for 56 days. Skin brightness (L*) rose about 1.9% at day 28 and 2.9% at day 56; dermatologist-scored spot darkness fell about 21% and 30% respectively; all participants showed some change. No placebo arm is described in the public report, and safety data are stated but not shown. Small, open, manufacturer-run.

Nonapeptide-1, in vitro

Manufacturer data report receptor binding and inhibition of α-MSH-stimulated melanin production in cultured melanocytes, with tyrosinase activity reduced by roughly a third at the concentrations tested †. Peer-reviewed independent data not found.

Graded B/—

Nonapeptide-1, topical clinical

Manufacturer volunteer data report reduced pigmentation of UV-induced spots and lightening of melasma-type patches over 1–3 months in small groups †; details not peer-reviewed.

Comparison with standard brighteners

No head-to-head trial of either peptide against hydroquinone, tretinoin, azelaic acid, tranexamic acid or niacinamide exists.

4Reported side effects and interactions

Literature-reported

Both are reported as non-irritating and non-sensitising in manufacturer safety testing; the oligopeptide-68 study claims good ocular and skin tolerance. No independent data.

Community-reported

well tolerated, with the usual complaint being lack of visible effect rather than irritation; peptides are often chosen by people who cannot tolerate hydroquinone or retinoids.

Theoretical. reducing melanin reduces natural UV protection in treated skin — sunscreen is not optional. A TGF-β-pathway mimic (oligopeptide-68) raises the same theoretical fibrosis/immune question noted for Syn-Coll (#183); no evidence at cosmetic doses. An MC1R antagonist (nonapeptide-1) could in principle blunt the anti-inflammatory and DNA-repair roles of α-MSH signalling in skin; unstudied and probably negligible at topical trace levels.

Interactions. pharmacologically contradictory with acetyl hexapeptide-1 (#187). Compatible with niacinamide, arbutin, tranexamic acid in formulation.

Markers researchers commonly monitor

No blood markers apply. Practical measures:

Marker	Why it's watched
*Colorimeter or standardised photographs (L value or Mexameter melanin index) of specific spots, same light, every 4 weeks for at least 8–12 weeks**
Modified MASI score if melasma is the target	the scoring system dermatologists use.
UV exposure and sunscreen adherence diary	without this the data are uninterpretable.
Forearm patch test before first use

Free for everyone. Safety information is never behind a paywall.

5Formulation and handling

Oligopeptide-68 is supplied as a liposomal dispersion; nonapeptide-1 as an aqueous solution. Both are water-based, heat-sensitive, added in the cool-down phase at 1–5% of finished formula. Not by consumers. Any brightening regimen in studies included daily broad-spectrum sunscreen. No calculator applies.

6Commonly studied alongside

Niacinamide, tranexamic acid, arbutin, azelaic acid, vitamin C derivatives (classical brightening actives); decapeptide-12 (another brightening peptide); acetyl hexapeptide-1 (#187, the pro-pigment opposite, for contrast).

Informational cross-links. Not stack recommendations.

7Regulatory status by region

Region	Status (checked —)
United States	Cosmetic ingredients; "brightening" and "evens tone" are cosmetic claims; claims to treat melasma or hyperpigmentation disorders are drug claims
European Union	Both CosIng-listed as skin-conditioning agents; permitted. Hydroquinone is banned in EU cosmetics, which is partly why peptide brighteners are marketed there
United Kingdom	Same as EU
Australia	Permitted cosmetic ingredients
South Africa	Permitted in cosmetics; South Africa has strict rules against skin-lightening claims and banned hydroquinone in cosmetics in 1990; "evens tone" wording is used instead †
Sport (WADA)	Not listed

8Open questions

Any placebo-controlled, peer-reviewed trial of either peptide? None found; the oligopeptide-68 study is open-label and manufacturer-run.
Durability of lightening after stopping — not reported.
Performance across skin types: the only clinical data for oligopeptide-68 are in Asian women; nothing published for darker skin types, where hyperpigmentation is a bigger concern.

9References

1Manufacturer article (undated). A peptide to influence the melanogenic symphony of skin pigmentation (oligopeptide-68). Cosmetics & Toiletries (sponsored; not peer-reviewed). PubMed
2Manufacturer article (undated). Advanced regulation via new pathway inhibition. Personal Care Magazine (sponsored; not peer-reviewed). PubMed
3Pillaiyar T, Manickam M, Namasivayam V (2017). Skin whitening agents: medicinal chemistry perspective of tyrosinase inhibitors. J Enzyme Inhib Med Chem. (background on pigment pathway) PubMed · DOI
4Abdel-Malek ZA et al. (2009). Melanocortins and the melanocortin 1 receptor: moving translationally towards melanoma prevention. Arch Biochem Biophys. (MC1R background) PubMed
5Schagen SK (2017). Topical peptide treatments with effective anti-aging results. Cosmetics. DOI

References are being resolved to PubMed/DOI identifiers; links search PubMed for the citation until then.

† Being confirmed by our reviewers against current sources.

10Community

forum threads →

community protocols include this →

Threads and protocols are visible to members. Joining is free.

Self-reported side effects Phase 2

Not enough data yet. 0 of the 50 members needed have logged this compound for 4+ weeks. We don't show anything below 50, so no one can be identified.

11Page history

31 Oct 2026Profile published — awaiting medical review

Licensed CC BY-NC-SA 4.0. Found an error? Report it · Editorial standards — corrections are logged here.